Emergent Biosolutions (EBS) is a commercial stage biotech that produces the only FDA approved anthrax vaccine. The company derives nearly all of its revenue from sales of BioThrax, its only marketed product, to the US Government. Currently, nearly all of Emergent's revenue comes from a contract with the Centers for Disease Control (CDC) that ends in September 2016.
To a cautious investor, a company with a single customer is bathed in red light. However, Emergent is attempting a transition. Lets see how its going.
On August 2, 2013, Emergent finished the acquisition of the Healthcare Protective Products Division (HPPD) from the privately held Italian giant, Bracco Diagnostics. The purchase included FDA approved Reactive Skin Decontamination...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: